Status:
COMPLETED
Body Weight, Aspirin Dose and Pro-resolving Mediators
Lead Sponsor:
NYU Langone Health
Conditions:
Body Weight
Eligibility:
All Genders
40-70 years
Phase:
PHASE4
Brief Summary
This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutr...
Eligibility Criteria
Inclusion
- 1\. Age between 40 and 70 years
Exclusion
- Anti-platelet medication use in the past 7 days
- Aspirin intolerance or allergy
- Known bleeding or clotting disorder
- Chronic inflammatory or connective tissue disease
- Immunological deficiency
- Diabetes mellitus
- Prior gastric or bariatric surgery
- Active smoking
- Platelet count \<100,000
- Use of omega-3 fatty acid supplementation
- Use of drugs or supplements known to inhibit COX-1/COX-2/lipoxygenases
- Corticosteroid use
- Recent initiation or change in dose of statin therapy
- Pregnancy
Key Trial Info
Start Date :
November 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 29 2025
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT04697719
Start Date
November 4 2021
End Date
January 29 2025
Last Update
May 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Health
New York, New York, United States, 10016